ADAMTS binding immunoglobulins

US11261260B2 · kind B2 · utility

Assignees

• Merck Patent GmbH · DE
• Ablynx N.V. · BE

Inventors

• Marie-Ange Buyse · Merelbeke, BE
• Guy Hermans · Merelbeke, BE
• Sven Lindemann · Darmstadt, DE
• Hans Guehring · Eltville am Rhein, DE
• Ralf Guenther · Griesheim, DE
• Roland Kellner · Heppenheim, DE

Key dates

• Filing date: Jun 4, 2018
• Grant date: Mar 1, 2022
• Expiry date: Jun 4, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein. Other aspects, embodiments, advantages and applications of the invention will become clear from the further description herein.